Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $26.4 million.

  • Ascendis Pharma A's Change in Account Payables fell 4499.99% to $26.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.0 million, marking a year-over-year decrease of 12833.29%. This contributed to the annual value of -$11.7 million for FY2025, which is 14068.26% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Change in Account Payables is $26.4 million, which was down 4499.99% from -$8.8 million recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Change in Account Payables peaked at $51.2 million during Q3 2021, and registered a low of -$42.9 million during Q1 2025.
  • Its 5-year average for Change in Account Payables is $5.9 million, with a median of $6.9 million in 2024.
  • Over the last 5 years, Ascendis Pharma A's Change in Account Payables had its largest YoY gain of 54450.28% in 2024, and its largest YoY loss of 27544.22% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Change in Account Payables (Quarter) stood at -$17.3 million in 2021, then skyrocketed by 238.15% to $23.9 million in 2022, then crashed by 145.28% to -$10.8 million in 2023, then skyrocketed by 544.5% to $48.1 million in 2024, then tumbled by 45.0% to $26.4 million in 2025.
  • Its last three reported values are $26.4 million in Q4 2025, -$8.8 million for Q3 2025, and $17.2 million during Q2 2025.